ANI Pharmaceuticals Inc. (ANIP)’s Financial Results Comparing With Chiasma Inc. (NASDAQ:CHMA)

Since ANI Pharmaceuticals Inc. (NASDAQ:ANIP) and Chiasma Inc. (NASDAQ:CHMA) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation of both companies.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ANI Pharmaceuticals Inc. 67 4.68 N/A 1.30 53.14
Chiasma Inc. 6 0.00 N/A -1.28 0.00

Demonstrates ANI Pharmaceuticals Inc. and Chiasma Inc. earnings per share, top-line revenue and valuation.

Profitability

Table 2 represents ANI Pharmaceuticals Inc. (NASDAQ:ANIP) and Chiasma Inc. (NASDAQ:CHMA)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals Inc. 0.00% 0.2% 0.1%
Chiasma Inc. 0.00% -65.1% -50%

Risk and Volatility

A 2.33 beta means ANI Pharmaceuticals Inc.’s volatility is 133.00% more than Standard and Poor’s 500’s volatility. Chiasma Inc.’s 1.51 beta is the reason why it is 51.00% more volatile than Standard and Poor’s 500.

Liquidity

The Current Ratio of ANI Pharmaceuticals Inc. is 0.9 while its Quick Ratio stands at 0.7. The Current Ratio of rival Chiasma Inc. is 2.2 and its Quick Ratio is has 2.2. Chiasma Inc. is better equipped to clear short and long-term obligations than ANI Pharmaceuticals Inc.

Analyst Recommendations

ANI Pharmaceuticals Inc. and Chiasma Inc. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ANI Pharmaceuticals Inc. 0 0 3 3.00
Chiasma Inc. 0 0 2 3.00

$75 is ANI Pharmaceuticals Inc.’s consensus target price while its potential downside is -7.12%. On the other hand, Chiasma Inc.’s potential upside is 114.29% and its consensus target price is $13.5. The data provided earlier shows that Chiasma Inc. appears more favorable than ANI Pharmaceuticals Inc., based on analyst opinion.

Institutional and Insider Ownership

The shares of both ANI Pharmaceuticals Inc. and Chiasma Inc. are owned by institutional investors at 82.7% and 66.4% respectively. 3.7% are ANI Pharmaceuticals Inc.’s share owned by insiders. Competitively, Chiasma Inc. has 0.1% of it’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ANI Pharmaceuticals Inc. -2.62% 1.01% 17.95% 31.3% 12.75% 53.58%
Chiasma Inc. -0.83% 9.07% 62.43% 46.94% 314.48% 93.25%

For the past year ANI Pharmaceuticals Inc.’s stock price has smaller growth than Chiasma Inc.

Summary

ANI Pharmaceuticals Inc. beats on 6 of the 9 factors Chiasma Inc.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for pain; Propafenone to treat arrhythmia; Propranolol ER and Inderal LA for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies using transient permeability enhancer technology platform. The company offers octreotide capsules, which is in Phase III clinical trial for the treatment of acromegaly, a condition that results in the bodyÂ’s production of excess growth hormone under the MYCAPSSA name. Chiasma, Inc. was founded in 2001 and is headquartered in Newton, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.